The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23344 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Vinay K Rathi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South …. Hauptthemen laut MEDLINE: Sinusitis, Asthma, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Commonwealth Fund, Arnold Ventures, NIDCD NIH HHS.
Abstract (Originalsprache)
Key points In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%–60%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.
- Division of Rhinology, Department of Otolaryngology-Head & Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Otolaryngology-Head & Neck Surgery, University of Florida, Gainesville, Florida, USA.
- Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
ORCID-Profile: Vinay K Rathi, Alan D Workman, Nicholas R Rowan
Förderung
- Commonwealth Fund
- Arnold Ventures
- NIDCD NIH HHS
- NIA NIH HHS
Zitieren
APA
Rathi, V. K., Soler, Z. M., Schlosser, R. J., Workman, A. D., Chapurin, N., Rowan, N. R., & Dusetzina, S. B. (2024). The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23344
Vancouver
Rathi VK, Soler ZM, Schlosser RJ, Workman AD, Chapurin N, Rowan NR, et al. The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23344
BibTeX
@article{Rathi2024,
author = {Rathi, Vinay K and Soler, Zachary M and Schlosser, Rodney J and Workman, Alan D and Chapurin, Nikita and Rowan, Nicholas R and Dusetzina, Stacie B},
title = {The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23344}
}
EUVIMED